SHIKARI® (QS-DEN) Denosumab ELISA (mAb-Based)
DEN-SPEC-DEN
SHIKARI® Denosumab ELISA has been especially developed for the specific and quantitative analysis of free denosumab in serum and plasma samples. SHIKARI® Denosumab Specific ELISA is optimized with Prolia® and biosimilars. For research use only (RUO).
Denosumab is a fully human monoclonal antibody that specifically binds to receptor activator of nuclear factor kappa-B ligand (RANKL), thereby inhibiting osteoclast formation, function, and survival. Quantification of circulating free denosumab may be useful in pharmacokinetic, immunogenicity, and biologic drug monitoring research. This assay utilizes highly specific anti-idiotypic monoclonal antibodies to selectively detect free denosumab molecules capable of target binding. The kit is intended for the quantitative determination of free denosumab in biological samples for research use only.
Research Use Only (RUO)
| Required Volume (µl) | 10 |
| Total Time (min) | 70 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 3 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| SDS | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Nanoparticle and Macromolecular Transfer across the Human Placental Barrier | Download | |
| Rahman, Mohammed Tanjimur, et al. "Nanoparticle-mediated synergistic drug combination for treating bone metastasis." Journal of Controlled Release 357 (2023): 498-510. | Visit Link | |
| Peterlin, Anton AN, et al. "Rethinking Bacterial Osteolysis: Translational Evidence From a Porcine Model and Fracture‐Related Infections." APMIS 134.2 (2026): e70151. | Visit Link |
